Hand bone densitometry in rheumatoid arthritis, a five year longitudinal study: an outcome measure and a prognostic marker.
OBJECTIVE
To investigate whether hand bone mineral content (BMC) measurement is an outcome measure for RA and whether the early changes in hand BMC predict functional disability.


METHODS
Tender and swollen joints in hands and body, HAQ score, Larsen score on hand radiographs, serum CRP, and hand BMC measurement by DXA were studied every six months for five years in 40 patients with early RA. At the final visit, patients completed the SF-36 and Duruoz hand function questionnaires.


RESULTS
All patients completed two years and 29 completed five years' follow up. Hand BMC worsened over the first three years (percentage loss from baseline: mean (SD) -5.5 (7.2), -7.5 (8.4), -9.8 (9.4)) and stabilised over last two years (-9.9 (8.8), -10 (7.8)). Baseline disease activity and function correlated with hand BMC loss at five years (swollen joints in hands: r=-0.38, p=0.043; swollen joints in body: r=-0.47, p=0.01; HAQ: r=-0.52, p=0.004). Percentage change in hand BMC over five years correlated with SF-36 physical function (r=0.61, p<0.01), hand function (r=-0.64, p<0.01), HAQ score (r=-0.63, p<0.01) at five years. Relative risk of bad hand functional outcome at five years was significantly higher for patients with hand BMC loss of >/=1.17 g (smallest detectable difference) than for patients with less bone loss within the first six months (OR=6.9, 95% CI 1.3 to 34.5, p<0.02).


CONCLUSIONS
Early loss of hand BMC in patients with RA is a composite marker of disease activity and functional status and can predict poor functional outcome.
Deodhar
A A
AA
Oregon Health Sciences University, Portland, OR, USA. Royal Cornwall Hospital, Truro, UK. deodhara@ohsu.edu
Brabyn
J
J
Pande
I
I
Scott
D L
DL
Woolf
A D
AD
D015502:Absorptiometry, Photon; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000503:physiopathology*; D015519:Bone Density; D002097:C-Reactive Protein / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006225:Hand / Q000503:physiopathology*; D006801:Humans; D008297:Male; D011379:Prognosis; D012720:Severity of Illness Index; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D002097:C-Reactive Protein